General Hospital Psychiatry
Volume 32, Issue 4 , Pages 426-432 , July 2010

Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment

  • Paul E. Holtzheimer, M.D., M.Sc.

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 404 727 9004; fax: +1 404 727 3233.
    • ,
  • Jason Veitengruber, M.D.

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
    • ,
  • Chia C. Wang, M.D., M.S.

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • ,
  • Meighan Krows, B.A.

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • ,
  • Hanne Thiede, D.V.M.

      Affiliations

    • Public Health Seattle & King County, Seattle, WA 98104, USA
    • ,
  • Anna Wald, M.D.

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • Department of Medicine, Epidemiology and Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    • Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98199, USA
    • ,
  • Peter Roy-Byrne, M.D.

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA

Received 7 November 2009 ,Accepted 2 February 2010.

References 

  1. Centers for Disease Control and Prevention . In: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention: 2006 Disease Profile. 2008;p. 17–26
  2. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–782
  3. Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006;40:322–335
  4. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–1457
  5. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923–931
  6. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–256
  7. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis. 2006;42:669–672
  8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  10. Wild TC, el-Guebaly N, Fischer B, Brissette S, Brochu S, Bruneau J, et al. Comorbid depression among untreated illicit opiate users: results from a multisite Canadian study. Can J Psychiatry. 2005;50:512–518
  11. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;
  12. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966
  13. Munoz M, Vazquez C, Koegel P, Sanz J, Burnam MA. Differential patterns of mental disorders among the homeless in Madrid (Spain) and Los Angeles (USA). Soc Psychiatry Psychiatr Epidemiol. 1998;33:514–520
  14. Gunderson JG, Morey LC, Stout RL, Skodol AE, Shea MT, McGlashan TH, et al. Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. J Clin Psychiatry. 2004;65:1049–1056
  15. Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571
  16. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry. 2000;157:867–876
  17. Golden J, Conroy RM, O'Dwyer AM. Reliability and validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory (Full and FastScreen scales) in detecting depression in persons with hepatitis C. J Affect Disord. 2007;100:265–269
  18. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104–112
  19. Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson SM, Thiede H, et al. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend. 2007;91(Suppl 1):S4–17
  20. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21:1923–1932
  21. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33quiz 34-57

☆ This study was approved by the Institutional Review Boards of all participating centers. Informed consent was obtained from all study participants.

PII: S0163-8343(10)00017-4

doi: 10.1016/j.genhosppsych.2010.02.001

General Hospital Psychiatry
Volume 32, Issue 4 , Pages 426-432 , July 2010

Article Tools

* Image Usage & Resolution